NEW YORK, March 26 – Dan Shochat, a former chief scientific officer and senior vice president at Coulter Pharmaceutical, has joined Deltagen as vice president of pharmaceutical development, the company said Monday.
At Deltagen, Shochat will lead the development of drugs for the potential treatment for Acute Myelogenous Leukemia (AML), and other future pharmaceutical development programs, Deltagen CEO William Matthews said in a statement. “Dr. Shochat's extensive expertise in drug discovery and development is a great asset to Deltagen as we move toward the development of our own biotechnology drugs," he said.
Prior to working at Coulter, Shochat, a biochemist by training, directed biotechnology development at the medical research division of American Cyanamid, where he led an investigation of monoclonal antibodies for the treatment of cancer.
In November of 2000, Deltagen of Menlo Park, Calif., said that it had licensed an approach to treating AML from the University of Kentucky that targeted CD123, a marker for certain types of leukemia cells.
Deltagen studies knock-out mice to provide functional genomic and target validation services for pharmaceutical customers, including GlaxoSmithKline, Merck, and Schering-Plough. GlaxoSmithKline and Pfizer subscribe to the company's database, DeltaBase, which contains information about mammalian gene function.